> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Glaxo, Adaptimmune Expand Cancer Therapy Collaboration
- URL: https://www.fdaweb.com/glaxo-adaptimmune-expand-cancer-therapy-collaboration/
- Published: 2016-02-03T12:00:00.000Z
- Updated: 2026-09-15T02:33:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5134673

> GlaxoSmithKline and Adaptimmune Therapeutics have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer program, an affinity enhanced T-cell immunotherapy (GSK3377794) targeting NY-ESO-1 toward pivotal trials in synovial sarcoma. The collaboration and licensing agreement was announced in 6/2014.  
>  
>  
>  
>  
>  
> “At GSK we’re progressing a pipeline of immuno-oncology therapies to stimulate anti-tumor immunity in patients,” the company says in a release. “With this expanded collaboration, we have the opportunity to accelerate the lead programme in synovial sarcoma toward pivotal trials and also to investigate several other tumour types and combine the T-cell therapy with immune-modulating therapies such as checkpoint inhibitors.” Under the expanded agreement, the companies will also explore development in myxoid round cell liposarcoma. Additionally, the companies may initiate up to eight proof-of-principle studies exploring combinations with other therapies, including checkpoint inhibitors.  
>  
>  
>  
>  
>  
> GSK says Adaptimmune’s affinity enhanced T-cell candidates are novel cancer immunotherapies that have been engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response. Using its proprietary technology, Adaptimmune has created a pipeline of affinity enhanced T-cell therapies targeting certain antigens, including cancer testis antigens such as NY-ESO.